Drug Approval | September 24, 2025
Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
The facility has been classified as Voluntary Action Indicated
The facility has been classified as Voluntary Action Indicated
The inspection was carried out between May 26, 2025 and May 31, 2025
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
The company received one observation in the Form-483
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
Zydus receives EIR for the API manufacturing facility at Ankleshwar
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
the inspection conducted from January 27 to January 31, 2025
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
Subscribe To Our Newsletter & Stay Updated
